|Articles|September 1, 1998

September 1998
Volume 4
Issue 9

Infectious Diseases and Anemia in a Sample of Out-of-Treatment Drug Users

Author(s)Isaac D. Montoya, PhD

Download PDF: Infectious Diseases and Anemia in a Sample of Out-of-Treatment Drug Users

Articles in this issue

almost 28 years ago

Article

Influence of a Critical Path Management Tool in the Treatment of Acute Myocardial Infarction

almost 28 years ago

Article

Assessing the Economic Value of Antihypertensive Medications

almost 28 years ago

Article

The Rationale for Skin Cancer Screening and Prevention

almost 28 years ago

Article

Effects of an Asthma Management Program on the Asthmatic Member: Patient-Centered Results of a 2-Year Study in a Managed Care Organization

almost 28 years ago

Article

Evaluating and Improving the Delivery of Heart Care: The University of Michigan Experience

almost 28 years ago

Article

A Case for Large-Core Biopsy Procedures in the Diagnosis of Breast Cancer

almost 28 years ago

Article

Mental Disorders in the Primary Care Sector: A Potential Role for Managed Care

almost 28 years ago

Article

Determining Whether Managed Care Formularies Meet the Needs of Pediatric Patients

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Infectious Diseases and Anemia in a Sample of Out-of-Treatment Drug Users

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next

Beyond GLP-1: The Biological Case for Dual Incretin Therapy in MASH

Stem Cell Transplant Outperforms DMTs in Drug-Resistant Relapsing MS

Home-Based Heart Failure Care Shows Comparable Safety to Continued Inpatient Care